CN105412584A - 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 - Google Patents
一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105412584A CN105412584A CN201510959592.4A CN201510959592A CN105412584A CN 105412584 A CN105412584 A CN 105412584A CN 201510959592 A CN201510959592 A CN 201510959592A CN 105412584 A CN105412584 A CN 105412584A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- licorice
- clematis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 208000001685 postmenopausal osteoporosis Diseases 0.000 title claims abstract description 18
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 26
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 26
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 26
- 229940010454 licorice Drugs 0.000 claims abstract description 26
- 241000756042 Polygonatum Species 0.000 claims abstract description 22
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 21
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 20
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 19
- 240000000031 Achyranthes bidentata Species 0.000 claims abstract description 17
- 241000218158 Clematis Species 0.000 claims abstract description 16
- 241000756943 Codonopsis Species 0.000 claims abstract description 14
- 241001116742 Drynaria Species 0.000 claims abstract description 14
- 241001435059 Artemisia argyi Species 0.000 claims abstract description 12
- 235000010894 Artemisia argyi Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 241000202807 Glycyrrhiza Species 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 23
- 235000006533 astragalus Nutrition 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 20
- 241001061264 Astragalus Species 0.000 claims description 19
- 210000004233 talus Anatomy 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 17
- 241000007126 Codonopsis pilosula Species 0.000 claims description 13
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 12
- 240000006891 Artemisia vulgaris Species 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 241000427159 Achyranthes Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000209020 Cornus Species 0.000 claims description 5
- 241000405414 Rehmannia Species 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 241000125175 Angelica Species 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- 235000003826 Artemisia Nutrition 0.000 claims description 2
- 244000030166 artemisia Species 0.000 claims description 2
- 235000009052 artemisia Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 241000431987 Neocheiropteris fortunei Species 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 20
- 210000003734 kidney Anatomy 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 13
- 210000004185 liver Anatomy 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000002435 tendon Anatomy 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 description 26
- 230000037182 bone density Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000000689 upper leg Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940126678 chinese medicines Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940057802 caltrate Drugs 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000219317 Amaranthaceae Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 241000207901 Cuscuta Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000029088 Phosphorus metabolism disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药技术领域,公开了一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法。该中药组合物包括以下重量份数的制备原料:艾叶5-25份、黄芪6-25份、党参9-30份、黄精9-15份、川芎6-15份、熟地黄9-15份、骨碎补3-9份、威灵仙3-9份、白芷3-9份、山茱萸6-12份、川牛膝3-9份和甘草1-10份。本发明采用天然中药,毒副作用小,具有益肝补肾、活血止痛、强筋固骨之功效,可有效治疗女性绝经后骨质疏松症。
Description
技术领域
本发明属于中药技术领域,尤其涉及一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法。
背景技术
绝经后骨质疏松症,属于原发性骨质疏松症Ⅰ型,是一种与衰老有关的常见病,主要发生在绝经后妇女(50~70岁),是由于雌激素缺乏导致骨量减少及骨组织结构变化,使骨脆性增加易于骨折,以及由骨折引起的疼痛、骨骼变形、出现合并症,乃至死亡等问题,严重地影响老年人的身体健康及生活质量,甚至缩短寿命,增加国家及家庭财力与人力负担。绝经后骨质疏松是多因素性疾病,遗传、生活方式、营养等均与发病有关,如骨质疏松症家族史、钙摄入不足、缺乏体力活动、大量吸烟及饮酒、早绝经或绝经前行双侧卵巢切除术者更易发病。
此外,骨质疏松症是一种隐匿发生的疾病,在没有发生骨折之前,往往没有任何症状,一旦发现驼背、身材变矮、或骨痛时,常常已经发生了骨折。因此,不能用临床症状进行诊断,疼痛的严重程度可用于判断治疗效果。
目前,激素替代是西医治疗绝经后骨质疏松症的首选疗法,已有大量研究证实绝经后妇女单独应用雌激素可以预防骨量的丢失,但单独使用或有增加乳腺癌和子宫内膜癌的危险,建议同时使用一种孕激素如黄体酮可减低癌的发生率。
传统中医理论认为“肾主骨、藏精、精生髓营骨”、“肝主筋、藏血,脾主肌肉、四肢、统血,脾主运化”。鉴于绝经期女性“多虚多瘀”的特点,在临床中使用健脾补肾、活血通络法得到重视并广泛使用。
目前公开的治疗绝经前骨质疏松症的发明专利有很多,例如:中国发明专利申请201310560861.0、201410466006.8、201510238699.X均公开了治疗绝经前骨质疏松症的中药配方。其中中国发明专利申请201510238699.X公开的用于治疗绝经后骨质疏松的药物,由以下重量配比的原料药材制备而成:菟丝子15份、芡实12份、神曲25份、骨碎补10份、鸡血藤7份、红藤8份、路路通10份、接骨木12份、青皮6份、郁金5份,但现有的治疗绝经前骨质疏松症的中药制剂缺乏针对性,具一定的毒副作用。
发明内容
本发明要解决的技术问题是提供一种中药组合物,使其充分发挥中药的调理作用,对治疗绝经前骨质疏松症有显著的治疗效果,并将其制成方便易用的成品制剂,使其能适应现代生活的节奏。
为实现本发明的目的,本发明技术方案如下:
本发明中药组合物包括如下重量份的中药材:
艾叶5-25份、黄芪6-25份、党参9-30份、黄精9-15份、川芎6-15份、熟地黄9-15份、骨碎补3-9份、威灵仙3-9份、白芷3-9份、山茱萸6-12份、川牛膝3-9份和甘草1-10份。
在该配比范围内,优选了3个疗效较为显著的配比:
配比1:艾叶5份、黄芪6份、党参9份、黄精9份、川芎6份、熟地黄9份、骨碎补3份、威灵仙3份、白芷3份、山茱萸6份、川牛膝3份和甘草1份。
配比2:艾叶15份、黄芪15份、党参20份、黄精12份、川芎10份、熟地黄12份、骨碎补6份、威灵仙6份、白芷6份、山茱萸9份、川牛膝6份和甘草5份。
配比3:艾叶25份、黄芪25份、党参30份、黄精15份、川芎15份、熟地黄15份、骨碎补9份、威灵仙9份、白芷9份、山茱萸12份、川牛膝9份和甘草10份。
相应地,本发明还提供所述中药组合物的制备方法,包括以下步骤:
1、按比例称取各味原料药材;
2、将艾叶、黄芪、党参、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草分别去杂质,洗净、烘干,粉碎成粗粉;
3、将黄芪、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草制备的粗粉混合,加8-11倍药材重量的纯化水,回流煎煮3次,每次1-3小时,过滤,合并滤液,浓缩成60℃时相对密度为1.15-1.20的水提浓缩液,备用;
4、将艾叶和党参制备的粗粉混合,加4-7倍量80-90%的乙醇,回流提取2-3次,每次5-8小时,合并醇提液,减压蒸馏,除去乙醇,滤液浓缩至60℃环境下相对密度为1.15-1.20的醇提浓液,备用;
5、将醇提浓缩液和水提浓缩液合并,减压干燥,粉碎研磨,过120目筛,得细粉,即为中药原料药细粉;
6、在中药原料药细粉中添加适当的辅料,以现代中药制剂常规工艺制成临床所需剂型,例如片剂、丸剂、散剂或胶囊剂等剂型。
本发明中药组方所用中药材的来源、性味、归经及功效:
艾叶:本品为菊科植物艾的干燥叶。味辛、苦,性温;归肝、脾、肾经;散寒止痛,温经止血。
黄芪:本品为豆科植物蒙古黄芪或膜荚黄芪的干燥根。味甘,性温;归心、肺、脾、肾经;补气固表,利尿托毒,排脓,敛疮生肌。
党参:本品为桔梗科植物党参、花党参(西党参)或川党参的干燥根。味甘,性平;归脾、肺经;补中益气,健脾益肺。
黄精:本品为百合科植物滇黄精、黄精或多花黄精的干燥根茎。味甘,性平;归脾、肺、肾经;补气养阴,健脾,润肺,益肾。
川芎:本品为伞形科植物川芎的干燥根茎。味辛,性温;归肝、胆、心包经;活血行气,祛风止痛。
熟地黄:为玄参科植物地黄或怀庆地黄的根茎,经加工蒸晒而成。味甘,性微温;归肝、肾经;滋阴补血,益精填髓。
骨碎补:本品为水龙骨科植物槲蕨的干燥根茎。味苦,性温;归肾、肝经;补肾强骨,续伤止痛。
威灵仙:本品为毛茛科植物威灵仙的干燥根及根茎。味辛、咸,性温;归膀胱经;祛风除湿,通络止痛。
白芷:本品为伞型科植物白芷或杭白芷的干燥根。味辛,性温;归胃、大肠、肺经;散风除湿,通窍止痛,消肿排脓。
山茱萸:本品为山茱萸科植物山茱萸的干燥成熟果肉。味酸、涩,性微温;归肝、肾经;补益肝肾,涩精固脱。
川牛膝:本品为苋科植物川牛膝的干燥根。味甘、微苦,性平;逐瘀通经,通利关节,利尿通淋。
甘草:本品为豆科植物甘草、胀果甘草或光果甘草的干燥根。味甘,性平;归心、肺、脾、胃经;补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。
本发明中药组方的配伍分析:
本发明中药组方依据中医对绝经、骨质疏松症的辨证认知,遵循中药的配伍理论,为了制成方便易用且疗效稳定的制剂,强化了药材的使用量。该组方是以艾叶、黄芪、党参为君药,补气养阴、止痛温经、益精填髓;以川芎、黄精、熟地黄为臣药,活血行气、除湿通络、补益肝肾;以山茱萸、骨碎补、威灵仙、白芷为佐药,补肾强骨、祛风除湿、通络止痛;以川牛膝和甘草为使药,调和诸药药性,诸药配合,相辅相成,协同作用,共奏强骨补肾、补气养阴、活血通经等功效,对女性绝经后骨质疏松症有十分显著的疗效。
与现有技术相比,本发明中药具有疗效好、标本兼治、侧重调理、毒副作用小等治疗优势,并且,本发明中药还可以制成普适性强、方便易用的成品制剂,克服了传统中药的不易携带服用、个体差异大等缺点,其制备工艺简便易行、制剂药效稳定、易于推广应用。
具体实施方式
以下将通过具体实施例对本发明进行进一步描述,本领域技术人员应理解,本发明除以下实施例外还可做出其他类似的改变获得相似的结果而不脱离本发明的内容和精神范围。
实施例一
本发明实施例1中药组合物包括如下重量份的中药材:
艾叶5份、黄芪6份、党参9份、黄精9份、川芎6份、熟地黄9份、骨碎补3份、威灵仙3份、白芷3份、山茱萸6份、川牛膝3份和甘草1份;
制备方法如下:
1、按比例称取各位原料药材;
2、将艾叶、黄芪、党参、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草分别去杂质,洗净、烘干,粉碎成粗粉;
3、将黄芪、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草制备的粗粉混合,加8倍药材重量的纯化水,回流煎煮3次,每次2小时,过滤,合并滤液,浓缩成60℃时相对密度为1.20的水提浓缩液,备用;
4、将艾叶和党参制备的粗粉混合,加4倍量90%的乙醇,回流提取2次,每次5小时,合并醇提液,减压蒸馏,除去乙醇,滤液浓缩至60℃环境下相对密度为1.20的醇提浓液,备用;
5、将醇提浓缩液和水提浓缩液合并,减压干燥,粉碎研磨,过120目筛,得细粉,即为中药原料药细粉;
6、在中药原料药细粉中添加适当的辅料,以现代中药制剂常规工艺制成片剂。
实施例二
本发明实施例2中药组合物包括如下重量份的中药材:
艾叶25份、黄芪25份、党参30份、黄精15份、川芎15份、熟地黄15份、骨碎补9份、威灵仙9份、白芷9份、山茱萸12份、川牛膝9份和甘草10份;
制备方法如下:
1、按比例称取各位原料药材。
2、将艾叶、黄芪、党参、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草分别去杂质,洗净、烘干,粉碎成粗粉;
3、将黄芪、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草制备的粗粉混合,加11倍药材重量的纯化水,回流煎煮3次,每次2小时,过滤,合并滤液,浓缩成60℃时相对密度为1.20的水提浓缩液,备用;
4、将艾叶和党参制备的粗粉混合,加7倍量90%的乙醇,回流提取3次,每次8小时,合并醇提液,减压蒸馏,除去乙醇,滤液浓缩至60℃环境下相对密度为1.20的醇提浓液,备用;
5、将醇提浓缩液和水提浓缩液合并,减压干燥,粉碎研磨,过120目筛,得细粉,即为中药原料药细粉;
6、在中药原料药细粉中添加适当的辅料,以现代中药制剂常规工艺制成胶囊剂。
实施例三
本发明实施例3中药组合物包括如下重量份的中药材:
艾叶15份、黄芪15份、党参20份、黄精12份、川芎10份、熟地黄12份、骨碎补6份、威灵仙6份、白芷6份、山茱萸9份、川牛膝6份和甘草5份;
制备方法如实施例一。
实施例四
本发明实施例4中药组合物包括如下重量份的中药材:
艾叶5份、黄芪6份、党参9份、黄精9份、川芎6份、熟地黄9份、骨碎补3份、威灵仙3份、白芷3份、山茱萸6份、川牛膝3份和甘草1份;
制备方法如实施例二。
本发明中药组合物药效学研究:
试验例一:本发明中药组合物对大鼠骨量的影响研究
1、实验目的及方法
目的:根据《中药新药药理学研究指南》的要求,研究本发明中药组合物在治疗绝经后骨质疏松症的主要药效学。取用本发明实施例一所得片剂,粉碎,加水,调成糊状,通过灌胃给药,观察本发明片剂高、中、低剂量对大鼠骨量的影响,骨量是目前评价骨质疏松症治疗效果的“金标准”。骨密度和骨钙含量可分别从不同侧面反映骨量,是骨质疏松症临床诊断以及评估疾病程度的客观的量化指标。
方法:60只雌性SD大鼠,体重250-310g,各批大鼠皆随机分为6组,各组分笼喂养。其50只切除双侧卵巢,术后给予青霉素防止感染;10只SD大鼠切除双侧卵巢旁各一块脂肪组织作假手术组,术后给予青霉素防止感染。术后45天,将去卵巢SD大鼠随机分成五组,按组合物高剂量组(2.4g/Kg)、组合物中剂量组(1.2g/Kg)、组合物低剂量组(0.4g/Kg)、阳性对照组和模型组(等容积生理盐水)灌胃给药,每日一次,连续90天。阳性对照组给予去胶囊壳后加水调成糊状的仙灵骨葆胶囊(贵州同济堂制药有限公司生产,国药准字Z20025337),灌胃给药(2.4g/Kg),每日一次,连续90天;假手术组等容积生理盐水灌胃给药,每日一次,连续90天。
标本采集在试验期间,每周称量体重一次。末次给药后禁食24小时后处死动物,剥离左右双侧股骨、胫骨进行测定。股骨骨钙含量的测定采用原子吸收分光光度法,从股骨的骨灰中取出30mg~40mg左右,精密称定,用盐酸溶解定容后测定;骨密度测定(DEXA法),应用XR-36型双能X线骨密度仪,分辨率为1.0×1.0mm,速度为40mm/s,测厚离体股骨的骨密度。
2、实验结果:如表1、表2所示。
表1药物对大鼠全身骨密度影响结果
注:与假手术组比较,▲▲P<0.01;与模型组比较*P<0.05,**P<0.01;与阳性对照组比较,#P<0.05。
表2药物对大鼠股骨干重及骨钙的影响
注:与假手术组比较,▲▲P<0.01;与模型组比较*P<0.05,**P<0.01,***P<0.001;与阳性对照组比较,#P<0.05,##P<0.01。
3、结论
本实验通过研究本发明中药组合物片剂高、中、低剂量对大鼠骨量的影响来判定本发明中药组合物在骨量方面的疗效。首先,本实验用60只大鼠作试验动物。连续90天给药,小鼠无一死亡,处死小鼠解剖观察各脏器未发现毒性反应,给药组与假手术组小鼠无任何差异,说明本发明中药组合物具有较佳安全性。其中50只切除双侧卵巢,大鼠的激素分泌会发生变化,与本发明中药组合物用于治疗绝经后的女性患者情况相似,另外10只切除双侧卵巢旁各一块脂肪组织作假手术组。模型组(去卵巢大鼠)股骨钙含量和骨密度与假手术组相比显著降低(P<0.01),说明去卵巢大鼠骨钙丢失严重。本发明中药组合物高、中、低剂量组的骨密度与模型组相比,各组能够显著增加骨质疏松大鼠的股骨钙含量和骨密度(P<0.05),并且均接近或高于对照组水平。可见,本发明中药组合物的三个剂量组均可增加大鼠的骨密度、股骨干重和骨钙含量,具有良好的治疗骨质疏松的效果。
试验二:本发明中药组合物对骨质疏松临床志愿者患者的临床疗效观察
一、病例及诊断标准
1、西医诊断标准:
诊断骨质疏松症应以骨密度减少2个标准差以上为基本依据,须鉴别是原发性骨质疏松症、还是继发性骨质疏松症。临床诊断时可参考年龄、病史、骨折和实验室检查等进行综合考虑。
参照世界卫生组织(WHO)推荐的诊断标准,基于DEXA测定:骨密度值低于同性别、同种族正常成人的骨峰值不足1个标准差属正常;降低1-2.5个标准差之间为骨量低下(骨量减少);降低程度等于和大于2.5个标准差为骨质疏松;骨密度降低程度符合骨质疏松诊断标准同时伴有一处或多处骨折时为严重骨质疏松。骨密度通常用T-Score(T值)表示,T值=(测定值-骨峰值)/正常成人骨密度标准差。T值≧-1.0为正常;-2.5<T值<-1.0为骨量低下;T值≦-2.5为骨质疏松。T值用于表示绝经后妇女和大于50岁男性的骨密度水平。
诊断标准为具备全身疼痛,多以腰背疼痛为主,酸软无力,逐渐加重,轻微外伤可致骨折;脊柱后突畸形;骨密度减少2个标准差以上者。
2、中医诊断标准:
按照《中药新药临床研究指导原则》(2002年)的“中药新药治疗骨质疏松症的临床研究指导原则”的评定要求制定。表现为:腰脊疼痛、酸软少力、步履艰难、头目眩晕、不能持重,舌质或偏红或淡,舌苔薄或薄白、脉沉细等症状,骨质疏松症见上述症候者。
二、临床试验
1、一般资料
所有入选的骨质疏松患者均为临床志愿者。治疗组100例,均为绝经后的女性患者;对照组100例,均为绝经后的女性患者。年龄为50岁-79岁,平均年龄64.5岁。两组年龄、症状等影响因素,经统计学处理,无显著性差异,符合分组条件。
2、治疗方法
治疗组:取用本发明实施例二中所得中药组合物胶囊剂,每次3粒,一天3次,连服3个月。
对照组:服用钙尔奇D片(国药准字H10950029,江苏Wyeth惠氏制药有限公司生产),一次1片,一日2次,连服3个月。
3、临床疗效评价标准
骨质疏松症骨密度疗效判定:
先计算骨密度变化值=(治疗后骨密度-治疗前骨密度)/疗前骨密度×100%
显效:骨密度变化率大于等于骨密度最小显著变化值;
有效:骨密度变化率在正负骨密度最小显著变化值之间;
无效:骨密度变化率小于负骨密度最小显著变化值。
其中骨密度最小显著变化值=2.77×(%CV),CV-变异系数。
总有效率=(显效+有效)/总病例数×100%2)
安全性观察指标:血、尿常规以及肝、肾功能、心电图等,用药前及疗程结束时各检测1次。
4、治疗结果,如表3所示。
表3治疗效果
5、结论
本次临床试验的临床志愿者患者均为绝经后的女性患者,未包含男性患者或由于其它原因引起的骨质疏松症患者,绝经女性一般年过50岁,因此选择年龄段在50-79岁之间;目前市面上治疗骨质疏松症的药物主要包括钙制剂、化学药和中成药,本试验采取钙尔奇作为对照组。从显效率和总有效率上也可看出,本发明中药组合物的显效率大于80%,总有效率大于90%,远高于对照组的显效率和总有效率。由此可见,本发明的中药组合物相对于西药,对治疗绝经后骨质疏松症具有显著的疗效。所有受试者经体格检查,肝肾功能正常,无内分泌疾病及钙、磷代谢紊乱,进一步证实本发明用于治疗绝经后骨质疏松症安全有效,具有推广应用的价值。
由于已经通过以上较佳实施例描述了本发明,在本发明的精神和/或范围内,任何针对本发明的替换/或组合来实施本发明,对于本领域的技术人员来说都是显而易见的,且包含在本发明之中。
Claims (6)
1.一种治疗女性绝经后骨质疏松症的中药组合物,其特征在于,所述中药组合物包括如下重量份的中药材:
艾叶5-25份、黄芪6-25份、党参9-30份、黄精9-15份、川芎6-15份、熟地黄9-15份、骨碎补3-9份、威灵仙3-9份、白芷3-9份、山茱萸6-12份、川牛膝3-9份和甘草1-10份。
2.根据权利要求1所述的治疗女性绝经后骨质疏松症的中药组合物,其特征在于,所述中药组合物包括如下重量份的中药材:
艾叶5份、黄芪6份、党参9份、黄精9份、川芎6份、熟地黄9份、骨碎补3份、威灵仙3份、白芷3份、山茱萸6份、川牛膝3份和甘草1份。
3.根据权利要求1所述的治疗女性绝经后骨质疏松症的中药组合物,其特征在于,所述中药组合物包括如下重量份的中药材:
艾叶15份、黄芪15份、党参20份、黄精12份、川芎10份、熟地黄12份、骨碎补6份、威灵仙6份、白芷6份、山茱萸9份、川牛膝6份和甘草5份。
4.根据权利要求1所述的治疗女性绝经后骨质疏松症的中药组合物,其特征在于,所述中药组合物包括如下重量份的中药材:
艾叶25份、黄芪25份、党参30份、黄精15份、川芎15份、熟地黄15份、骨碎补9份、威灵仙9份、白芷9份、山茱萸12份、川牛膝9份和甘草10份。
5.根据权利要求1-4任一所述的治疗女性绝经后骨质疏松症的中药组合物,其特征在于,所述中药组合物被制成片剂、丸剂、散剂和胶囊剂。
6.根据权利要求1-5任一所述的治疗女性绝经后骨质疏松症的中药组合物的制备方法,其特征在于,所述中药组合物的制备方法包括以下步骤:
步骤1、按比例称取各味原料药材;
步骤2、将艾叶、黄芪、党参、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草分别去杂质,洗净,烘干,粉碎成粗粉;
步骤3、将黄芪、黄精、川芎、熟地黄、骨碎补、威灵仙、白芷、山茱萸、川牛膝和甘草制备的粗粉混合,加8-11倍药材重量的纯化水,煎煮2-3次,每次1-3小时,过滤,合并滤液,浓缩成55℃-65℃时相对密度为1.15-1.20的水提浓缩液,备用;
步骤4、将艾叶和党参制备的粗粉混合,加4-7倍量80-90%的乙醇,回流提取2-3次,每次5-8小时,合并醇提液,减压蒸馏,除去乙醇,滤液浓缩至55℃-65℃环境下相对密度为1.15-1.20的醇提浓缩液,备用;
步骤5、将步骤3所得水提浓缩液和步骤4所得醇提浓缩液合并,减压干燥,粉碎研磨,过100-200目筛,即为本发明中药组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510959592.4A CN105412584A (zh) | 2015-12-21 | 2015-12-21 | 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510959592.4A CN105412584A (zh) | 2015-12-21 | 2015-12-21 | 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105412584A true CN105412584A (zh) | 2016-03-23 |
Family
ID=55491431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510959592.4A Withdrawn CN105412584A (zh) | 2015-12-21 | 2015-12-21 | 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105412584A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117959361A (zh) * | 2024-04-01 | 2024-05-03 | 吉林浩泰健康产业发展股份有限公司 | 一种用于强筋壮骨的药物组合物及制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103550476A (zh) * | 2013-11-13 | 2014-02-05 | 崔合芳 | 一种治疗绝经后骨质疏松症的药物组合物及其制备方法 |
CN103751529A (zh) * | 2014-02-11 | 2014-04-30 | 王雪雁 | 治疗女性绝经后骨质疏松症的药物组合物及其制备方法 |
-
2015
- 2015-12-21 CN CN201510959592.4A patent/CN105412584A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103550476A (zh) * | 2013-11-13 | 2014-02-05 | 崔合芳 | 一种治疗绝经后骨质疏松症的药物组合物及其制备方法 |
CN103751529A (zh) * | 2014-02-11 | 2014-04-30 | 王雪雁 | 治疗女性绝经后骨质疏松症的药物组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
辛杰等主编: "《骨质疏松诊断与治疗进展》", 30 September 2011, 天津科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117959361A (zh) * | 2024-04-01 | 2024-05-03 | 吉林浩泰健康产业发展股份有限公司 | 一种用于强筋壮骨的药物组合物及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105663607B (zh) | 一种中药组合物及其制备方法和用途 | |
CN104491801A (zh) | 一种治疗急慢性胃炎的中药制剂及其制备方法 | |
CN102210844B (zh) | 一种治疗慢性肝炎的中药组合物及其制备方法 | |
CN104940509A (zh) | 一种药物组合物用于制备治疗妇科出血症药物中的用途 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN102120020B (zh) | 一种治疗乳腺增生病和子宫肌瘤的药物组合物及其制备方法 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN101926903A (zh) | 用于治疗面神经麻痹的中药制剂 | |
CN103341092A (zh) | 一种治疗萎缩性阴道炎的散剂制备方法 | |
CN100467043C (zh) | 一种治疗骨质疏松症的中药及制备方法 | |
CN103301353B (zh) | 一种治疗萎缩性阴道炎的药物组合物 | |
CN103285284B (zh) | 一种治疗老年性阴道炎的药物组合物 | |
CN103446445B (zh) | 治疗气阴两虚型慢性支气管炎的中药制剂及其制备方法 | |
CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
CN105412584A (zh) | 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 | |
CN105327121A (zh) | 一种治疗女性绝经后骨质疏松症的中药组合物及其制备方法 | |
CN101732469B (zh) | 一种中药组合物在制备治疗失音症药物中的应用 | |
CN105012507A (zh) | 一种治疗骨质疏松症的中药组合物及其制备方法 | |
CN104547859A (zh) | 一种中药制剂用于制备治疗慢性气管炎药物中的用途 | |
CN104306847A (zh) | 一种六味补气胶囊及其制备工艺 | |
CN105456657A (zh) | 治疗女性绝经后骨质疏松症的中药组合物及其制备方法 | |
CN108310206B (zh) | 一种用于预防或治疗骨质疏松症的中药组合物及其制备方法和应用 | |
CN100333777C (zh) | 改善放化疗后肠胃功能的药物 | |
CN104225004A (zh) | 一种含巴西人参的辅助抗肿瘤中药制剂 | |
CN105535817A (zh) | 一种含艾叶的治疗颈椎病的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |
|
WW01 | Invention patent application withdrawn after publication |